Strategic Funding Alentis recently completed a large Series D financing totaling approximately $181M and $181.4M across multiple rounds, signaling strong investor confidence and potential for collaboration or licensing opportunities to accelerate CLDN1 program development.

Executive Leadership New CEO Mark Pruzanski joined in October 2025, complemented by recent additions to the executive team, indicating a strategic shift toward aggressive clinical advancement and potential partnerships to scale development, manufacturing, and commercialization efforts.

Clinical Focus The company is advancing first-in-class CLDN1 antibody-drug conjugates and antibodies for oncology and multi-organ fibrosis, presenting multiple collaboration avenues with biopharma firms seeking CLDN1-targeted therapies or ADC platform partnerships.

Scale & Capabilities With a Basel, Switzerland base and a mid-size team, Alentis combines clinical-stage momentum with expanding funding, creating opportunities for contract development and manufacturing, data-sharing collaborations, and joint ventures to accelerate trials.

Market Positioning Alentis’ focus on an untapped CLDN1 target and its strategy to pursue both cancer and fibrotic indications positions it as a potential partner for biotech companies needing novel, targeted modalities; potential buyers include CROs, investors seeking co-development, or license-out deals.